KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

Shai Shimony, H Moses Murdock, Julia Keating, Harrison K Tsai, Archana Sasi, Christopher J Gibson, Stefan Faderl, Anthony Wagner, Nalina Dronamraju, Tara L Lin, Thomas Prebet, Jorge E Cortes, Geoffrey L Uy, Jeffrey E Lancet, Christopher R Reilly, Donna Neuberg, Richard M Stone, R Coleman Lindsley

Blood Adv 10(8) 2854-2864

PMID41628350
PMCIDPMC13133533
DOI10.1182/bloodadvances.2025019378
发表日期2026-02-02
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

CPX-351 was approved for the treatment of acute myeloid leukemia (AML) using now-outdated definitions of AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML. We evaluated whether the overall survival (OS) benefit of CPX-351 over standard cytarabine plus anthracycline (7+3) therapy is confined to molecularly defined AML subgroups by performing DNA sequencing in 184 patients enrolled in the pivotal phase 3 randomized trial. Patients were categorized hierarchically based on gene mutations: (1) TP53-AML, (2) DDX41-AML, (3) myelodysplasia-related AML (AML-MR) defined by the World Health Organization fifth edition criteria, or (4) other-AML. TP53-AML was subclassified as single (TP53single) or multihit (TP53multi) based on the number of alleles altered via mutation, deletion, or copy neutral loss of heterozygosity. Two-year OS differed significantly across molecular subgroups: TP53-AML (7%), AML-MR (19%), other-AML (37%), and DDX41-AML (70%) (P< .001). CPX-351 improved survival in patients with AML-MR compared with 7+3 (median, 9.7 vs 6.8 months; P = .037), with no benefit in TP53-AML or other-AML. For patients undergoing transplantation, CPX-351 improved 2-year survival (76% vs 27%; P< .01), an effect primarily observed in AML-MR. Multivariable analysis confirmed the independent association with survival of both CPX-351 and hematopoietic cell transplantation in AML-MR. TP53multi demonstrated significantly worse survival than TP53single (median, 3.8 vs 7.0 months; P = .004). The OS benefit of CPX-351 observed in the trial was driven by AML-MR with no benefit of CPX-351 in TP53-AML, in which the primary prognostic factor was allelic state. This trial was registered at www.clinicaltrials.gov as #NCT01696084.

KM 提取结果

4 个 Figure · 8 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 1

Figure 1. Genetic reclassification and association with survival. (A) Comutation plot of mutations present at AML diagnosis in the 184 patients with available samples enrolled in the CLTR0310-301 study per the 3 clinical classifications. Each column represents an individual patient, with the rows representing genes or cytogenetic abnormalities and the colored bars representing mutations. The percentage at the end of each row represents the percentage of patients in each clinical group harboring a mutation in that gene. The colored bars represent the hierarchical genetic classification as follows: TP53 (green), DDX41 (yellow), AML-MR (blue), and other mutations (red). (B) OS by clinical classification among sequenced patients. (C) OS by genetic classification. Abn, abnormality; MRC-cyto, MRC by cytogenetics; MRC-secondary, MRC by prior MDS or CMML; ITD, internal tandem duplication; TKD, tyrosine kinase domain.

B

Overall Survival

Figure 1 · Panel B

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

Overall Survival

Figure 1 · Panel C

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel C 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure4 个面板

Figure 2

Figure 2. OS by genetic classification and treatment arm (CPX-351 vs 7+3). (A) OS in AML-MR by treatment. (B) OS in TP53 -AML by treatment arm. (C) OS in other-AML by treatment arm. (D) OS in DDX41 -AML by treatment arm. Time is measured from random assignment.

A

OS

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
B

OS

Figure 2 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

OS

Figure 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

OS

Figure 2 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
KM Figure1 个面板

Figure 3

Figure 3. Transplantation and clinical outcomes in AML-MR. (A) Simon-Makuch plot for OS in patients with AML-MR in which allogeneic HCT is considered as a time-dependent covariate. (B) Multivariable OS Cox regression analysis of patients with AML-MR. HCT is measured as a time-varying covariate.

A

Overall Survival

Figure 3 · Panel A

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 3 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure1 个面板

Figure 4

Figure 4. TP53 allelic status and outcome. (A) Lollipop plot of pathogenic TP53 mutations among patients enrolled in the CLTR0310-301 study irrespective of treatment arm allocation. Each lollipop corresponds to a mutation, with the height of the lollipop being proportional to the frequency of that mutation in the cohort. Missense mutations are depicted above the bar, whereas truncating variants are depicted below. (B) Ridge/rain plot depicting the distribution of TP53 variant allele fractions according to allelic status. (C) Comutation plot of TP53 -mutated patients according to allelic status. Each column represents a patient and each row represents a gene mutation or genetic abnormality, with the colored bars indicating the presence of that genetic abnormality. (D) OS in the overall cohort by TP53 mutation and allelic status. Del, deletion; TAD, transactivation domain.

D

OS

Figure 4 · Panel D

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel D 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 3 条,实际恢复 2 条曲线 2:off origin start曲线 3:off origin start曲线 3:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 5Figure 5. Count recovery among responders and early mortality. (A) Neutrophil count recovery to ≥500 × 10 9 /L based on genetic classification and treatment arm. (B) Platelet count recovery to ≥50 × 10 9 /L based on genetic classification and treatment arm. (C) Rate of early mortality by genetic classification. Early death was defined as death at day 30 or earlier or between days 31 and 60. ANC 500, absolute neutrophil count ≥500 × 10 9 /L; PLT 50, platelet count ≥50 × 10 9 /L.
非 KM Figure